At a glance
ClinicalIndex Comparison RecordN/ACompleted· 8 enrolled
Drug / intervention
VORTX Rx treatmentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors (Theresa Study)
In Brief
A clinical study evaluating VORTX Rx treatment for Carcinoma, Hepatocellular and Liver Metastases. Completed, enrolled 8 participants across 3 sites.
Detailed Summary
Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular, Liver Metastases
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedNov 2018
Primary CompletionMay 2019
Study CompletionJul 2019
TodayJul 2026
First PostedNov 14, 2018
Enrollment StartMar 21, 2018
Primary CompletionMay 15, 2019
Study CompletionJul 17, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.6 years ago
Interventions
VORTX Rx treatmentdevice
Cavitation-based cellular destruction using focused ultrasound